The FDA approved a new medicine from Denali Therapeutics for Hunter syndrome, a rare genetic disorder. The approval is notable following a recent string of FDA rejections for rare disease drugs.
FDA approval of Denali's Hunter syndrome drug
- ▪The FDA approved Denali Therapeutics' drug Avlayah for Hunter syndrome on Wednesday, March 25, 2026
- ▪Denali Therapeutics' Hunter syndrome drug is called Avlayah
Shifting FDA stance on rare disease therapies
- ▪The FDA rejected Regenxbio's Hunter syndrome gene therapy in February 2026
- ▪The FDA has issued other rejections of rare disease therapies beyond the Regenxbio decision
- ▪The FDA's requirement for more clinical data from Regenxbio represents a higher standard of evidence that could take the company years to meet
- ▪FDA officials have signaled they are scrutinizing rare disease drugs more closely
- ▪The FDA told Regenxbio that the company needed to produce more clinical data for its Hunter syndrome gene therapy
- ▪The FDA has recently taken tougher stances on rare disease drugs
Impact on patient advocates and industry concerns
- ▪Patient advocates were worried about the fate of Denali Therapeutics' drug Avlayah following recent FDA rejections of rare disease therapies
Perspective of Patient advocates for rare disease treatments
- ▪Patient advocates view the approval of Denali Therapeutics' Avlayah as a positive signal amid concerns about FDA accessibility for rare disease therapies
- ▪Patient advocates fear that higher FDA evidence standards for rare disease drugs could delay access to potentially life-saving treatments
Perspective of Denali Therapeutics
- ▪Denali Therapeutics' successful FDA approval of Avlayah demonstrates that rare disease drugs can still gain approval under stricter regulatory scrutiny
Perspective of Regenxbio
- ▪Regenxbio's Hunter syndrome gene therapy rejection illustrates the challenges biotechnology companies face under the FDA's increased evidentiary requirements for rare diseases
- ▪Regenxbio must invest additional years and resources to generate the clinical data the FDA requires for its Hunter syndrome gene therapy
Story comments
Loading comments…